Key facts
- Fidabio’s last known valuation is $30.7M (Dec 2025).
- It has raised $16.4M.
- Notable investors include Denmark's Export and Investment Fund, Fåhraeus Startup and Growth Fund, Horizon 2020.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Fidabio
- ·The full record, as it builds
Funding rounds
No funding rounds for Fidabio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fidabio
Operator of a biophysics platform intended to ease the process of quantitative characterization and quantification of proteins and nanoparticles. The company's platform utilizes a new proprietary technology that allows early detection of immune responses, makes affinity assessment significantly faster than existing methods, and requires small sample volumes, enabling researchers and drug developers to study complex interactions and quantifications using simple workflows with direct measurement in purified and unpurified matrices, labeled and label-free.
- Sector
- Healthcare
- HQ
- Soborg, Denmark
- Founded
- 2012
- Employees
- 29
- Website
- fidabio.com/
- Ownership
- Privately Held (backing)
Fidabio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fidabio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fidabio in its N-PORT filings yet. We sweep new filings monthly.